Authors
Latest:
Dr. Twelves Highlights Findings From the 2012 SABCSChristopher Twelves, MD, Professor and Honorary Consultant in Medical Oncology, University of Leeds, highlights key findings from the 2012 San Antonio Breast Cancer Symposium, which took place in December 2012.
Latest:
Radiation for Chemo-Sensitization: A Phase II Trial of Cetuximab and Docetaxel With Low-Dose Fractionated Radiation for Recurrent Unresectable Locally Advanced Head and Neck CarcinomaThis study evaluates low dose radiotherapy in combination with docetaxel and cetuximab in patients with recurrent, unresectable squamous cell carcinoma of the head and neck initially treated with definitive chemo-radiation therapy.
Latest:
Dr Kim on the Importance of the FDA Approval of Repotrectinib for ROS1+ NSCLCChul Kim, MD, MPH, discusses the impact of optimizing rare targets in lung cancer, highlighting the FDA approval of repotrectinib in ROS1-positive disease.
Latest:
Combined Radiation Therapy and Checkpoint Inhibition in Lymphoma: A Case Report and Brief ReviewThe emergence of immune checkpoint inhibitors as an effective treatment strategy is a result of increased understanding of the elaborate relationship between tumor cells, their microenvironment and the host immune response.
Latest:
Renal Cell Carcinoma: Future Directions in CareLooking toward the future management of renal cell carcinoma, experts consider treatment strategies for bone metastasis, brain metastasis, and VHL disease.
Latest:
Dr. Lee on Second-Line Treatment Options in RCCChung-Han Lee, MD, PhD, discusses second-line treatment options in renal cell carcinoma.
Latest:
Dr Lee on Extended Follow-Up With Pembrolizumab and Lenvatinib in Pretreated mRCCChung-Han Lee, MD, PhD, discusses the final results of the phase 2 cohort of a phase 1/2 trial evaluating lenvatinib plus pembrolizumab in patients with pretreated metastatic clear cell renal cell carcinoma.
Latest:
Androgen Deprivation Therapy and Cardiovascular Risk in Prostate CancerAccumulating evidence suggests that androgen deprivation therapy for prostate cancer increases the risk of cardiovascular morbidity and mortality, though not all studies demonstrate an association
Latest:
Dr. O'Sullivan on Individualized HER2-Targeted Therapy in HER2+ Breast CancerCiara O'Sullivan, MB, BCh, senior associate consultant, assistant professor of oncology, Division of Medical Oncology, Department of Oncology, Mayo Clinic, discusses how HER2-targeted treatment can be more individualized in the treatment of patients with HER2-positive breast cancer.
Latest:
Wholesale Medicine: The Why and How of Physician Engagement in Healthcare PolicyThis article discusses the wholesale side of medicine, exploring the why and how of physician involvement in healthcare policy.
Latest:
Clinical Oncology in the 21st Century: Reflections on how Healthcare Providers Should Manage Their Public Personas on Social MediaIt is important that clinicians engage with social media, since reputations are at risk by not knowing what is being said, shared, and discussed online about them online.
Latest:
Ruxolitinib Versus Best Available Therapy for Polycythaemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomised TrialClaire Harrison, MD, reviews the use of ruxolitinib in patients who are ineligible for hydroxycarbamide for the management of polycythemia vera (PV).
Latest:
Phase I Study With Prexasertib and LY3300054 in Ovarian CancerClaire Manuszak, BS, discusses a phase I study (NCT03495323) with prexasertib (LY2606368) and LY3300054 in ovarian cancer.
Latest:
Dr Verschraegen on Toxicities Associated with Single-agent vs Doublet Immunotherapy in MelanomaClaire F. Verschraegen, MD, discusses adverse effects that are commonly associated with the use of single-agent nivolumab vs the combination of ipilimumab plus nivolumab in melanoma.
Latest:
Advances in the Management of Hepatic and Pancreatic MalignanciesPerry Shen, MD, FACS, and Clancy Clark, MD, from Wake Forest Baptist Health Comprehensive Cancer Center, discuss advances in the management of hepatic and pancreatic malignancies.
Latest:
Dr Hwang on Considering AEs Associated With FDA-Approved Agents in Nonmetastatic Prostate CancerClara Hwang, MD, discusses adverse effects associated with FDA-approved agents for patients with nonmetastatic prostate cancer.
Latest:
Dr. Low on Osimertinib Versus Dacomitinib in EGFR-Mutant NSCLCClarke A. Low, MD, discusses osimertinib (Tagrisso) versus dacomitinib (Vizimpro) in EGFR-mutant non–small cell lung cancer.
Latest:
Dr. Grigg Discusses CABOSUN Trial in mRCCClaud Grigg, MD, medical oncologist, Levine Cancer Institute, Atrium Health, discusses the design and results of the CABOSUN trial in metastatic renal cell carcinoma.
Latest:
Dr. Grigg on the Results of the CheckMate-214 Trial in RCCClaud M. Grigg, Jr., MD, discusses the results of the CheckMate-214 trial in renal cell carcinoma.
Latest:
Dr. Denham on Hyperprogression in Patients With NSCLCClaude Denham, MD, Baylor Medical Center, discusses the manifestation of hyperprogression in patients with non–small cell lung cancer (NSCLC) who have been treated with immunotherapy.
Latest:
Lung Cancer Screening Needs to Remain State-of-the-ArtIn CT screening for lung cancer, the regimen of screening is a critical factor in diagnosing lung cancer early while limiting unnecessary tests and invasive procedures.
Latest:
Dr. Isaacs on the Evolving Treatment Landscape in HER2+ Breast CancerClaudine Isaacs, MD, discusses the rapidly evolving HER2-positive breast cancer armamentarium.
